High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$13.3M
$13,282,069
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
| DYN |
Dyne Therapeutics, Inc.
|
Director
10b5-1 Sell
|
2026-03-10 | $10,000,327MEGAx3 | S | Form 4 |
| DYN |
Dyne Therapeutics, Inc.
|
Director
10b5-1 Sell
|
2026-03-09 | $3,148,987Large | S | Form 4 |
| DYN |
Dyne Therapeutics, Inc.
|
CEO
Sell to Cover
|
2026-03-05 | $40,707 | S | Form 4 |
|
DYN
S
Dyne Therapeutics, Inc.
Friedl-Naderer Johanna
• Officer • Chief Commercial Officer
Sell to Cover
2026-03-05
$2,205
|
||||||
| DYN |
Dyne Therapeutics, Inc.
|
Officer • Chief Commercial Officer
Sell to Cover
|
2026-03-05 | $2,205 | S | Form 4 |
|
DYN
S
Dyne Therapeutics, Inc.
Kerr Douglas
• Officer • Chief Medical Officer
Sell to Cover
2026-03-05
$13,470
|
||||||
| DYN |
Dyne Therapeutics, Inc.
|
Officer • Chief Medical Officer
Sell to Cover
|
2026-03-05 | $13,470 | S | Form 4 |
| DYN |
Dyne Therapeutics, Inc.
|
CEO
Sell to Cover
|
2025-12-05 | $55,157 | S | Form 4 |
|
DYN
S
Dyne Therapeutics, Inc.
Friedl-Naderer Johanna
• Officer • Chief Commercial Officer
Sell to Cover
2025-12-05
$2,984
|
||||||
| DYN |
Dyne Therapeutics, Inc.
|
Officer • Chief Commercial Officer
Sell to Cover
|
2025-12-05 | $2,984 | S | Form 4 |
|
DYN
S
Dyne Therapeutics, Inc.
Kerr Douglas
• Officer • Chief Medical Officer
Sell to Cover
2025-12-05
$18,234
|
||||||
| DYN |
Dyne Therapeutics, Inc.
|
Officer • Chief Medical Officer
Sell to Cover
|
2025-12-05 | $18,234 | S | Form 4 |